Jubilant Pharmova’s subsidiary, Jubilant HollisterStier (JHS), has commissioned a new sterile fill‑and‑finish production line in its Spokane, Washington facility. The project cost US$ 132 million and is the third line at the site. With this line now active, Spokane’s capacity rises by 50 percent.
JHS uses advanced isolator technology in the new line to enhance sterility control, accuracy, and throughput. The facility is built to meet high regulatory standards and will support a wide range of injectable drug programs.
This step is part of a multi‑phase expansion. When the fourth line is added, JHS expects to double its total sterile injectable capacity by the end of fiscal year 2028. The move aims to reduce reliance on offshore manufacturing and strengthen the US domestic supply chain.
The investment responds to strong demand and a global shortfall in sterile vials. JHS sees opportunities as pharma companies seek high-quality US manufacturing capacity. The company plans to reach full utilization of the new line within three years.
With this expansion, Jubilant Pharmova reinforces its role in global pharmaceutical manufacturing. The new capacity positions it to better serve clients, improve supply chain resilience, and meet growing demand for injectable medicines in the US and beyond.
#LineCommissioning
#JubilantPharmova
#SterileInjectables
#SpokaneFacility
#USPharmaExpansion
#SterileFillFinish
#IsolatorTechnology
#InjectableCapacity
#PharmaSupplyChain
#USManufacturing
